NASDAQ:ZSQR Coeptis Therapeutics (ZSQR) Stock Price, News & Analysis $4.54 +0.76 (+20.11%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Coeptis Therapeutics Stock (NASDAQ:ZSQR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Coeptis Therapeutics alerts:Sign Up Key Stats Today's Range$3.66▼$4.7550-Day Range$2.29▼$5.3352-Week Range$2.11▼$21.41Volume622,977 shsAverage Volume284,678 shsMarket Capitalization$240.62 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Coeptis Therapeutics Holdings, Inc. was a U.S.-based biopharmaceutical company focused on developing therapies for cancer and other serious diseases. Its work centered on immuno-oncology and cellular immunotherapy, with the goal of using the body’s immune system to identify and attack cancer cells. The company’s development activities included the G-NII platform, obtained through its combination with VyGen-Bio. The platform was designed to support the development of targeted cell therapies, including candidates intended to harness natural killer cells and other immune-system components. Coeptis also pursued research collaborations and licensing opportunities to advance its therapeutic pipeline. Coeptis was historically led by David Mehalick, who served as chairman and chief executive officer. Public records have generally identified the company with the Nasdaq ticker COEP rather than ZSQR, so the ticker supplied for this request should be independently verified.AI Generated. May Contain Errors. Read More Coeptis Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks8th Percentile Overall ScoreZSQR MarketRank™: Coeptis Therapeutics scored higher than 8% of companies evaluated by MarketBeat, and ranked 560th out of 595 stocks in the technology sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingCoeptis Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageCoeptis Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Coeptis Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Coeptis Therapeutics is -2.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Coeptis Therapeutics is -2.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCoeptis Therapeutics has a P/B Ratio of 1.73. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.24% of the float of Coeptis Therapeutics has been sold short.Short Interest Ratio / Days to CoverCoeptis Therapeutics has a short interest ratio ("days to cover") of 10.13, which indicates bearish sentiment.Change versus previous monthShort interest in Coeptis Therapeutics has recently decreased by 1.09%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCoeptis Therapeutics does not currently pay a dividend.Dividend GrowthCoeptis Therapeutics does not have a long track record of dividend growth. News and Social Media2.4 / 5News Sentiment0.89 News SentimentCoeptis Therapeutics has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Technology companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Coeptis Therapeutics this week, compared to 2 articles on an average week. Company Ownership3.0 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $3,920.00 in company stock, which represents 0.0016% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Coeptis Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $3,920.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders24.25% of the stock of Coeptis Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions13.88% of the stock of Coeptis Therapeutics is held by institutions.Read more about Coeptis Therapeutics' insider trading history. Receive ZSQR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Coeptis Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ZSQR Stock News HeadlinesAnalyzing SoundHound AI (NASDAQ:SOUN) & Coeptis Therapeutics (NASDAQ:ZSQR)September 27 at 3:58 AM | americanbankingnews.comZ Squared Inc. CEO David Halabu Discusses AI Data Center Strategy on Two Investor PodcastsSeptember 18, 2026 | prnewswire.comMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on December 8th. Altucher is hosting a free masterclass revealing what he says is locked inside a sealed briefcase detailing Musk's plans. Attendees who join early can also access a $1,000 bonus offer included with the presentation.September 28 at 1:00 AM | Paradigm Press (Ad)Head-To-Head Comparison: Coeptis Therapeutics (NASDAQ:ZSQR) & Datavault AI (NASDAQ:DVLT)September 17, 2026 | americanbankingnews.comZ Squared Acquires Energized Arkansas Campus to Advance AI Infrastructure StrategySeptember 9, 2026 | prnewswire.comZ Squared CEO to Shareholders: "The Scarcest Thing in AI is Not Chips. It is Power.August 14, 2026 | prnewswire.comZ Squared Inc. Signs Definitive Agreement to Acquire 100% of Paradox Data and Its Union County CampusAugust 3, 2026 | prnewswire.comZ Squared Inc. Terminates At-The-Market Sales Agreement and Committed Equity Forward Purchase AgreementJuly 17, 2026 | prnewswire.comSee More Headlines ZSQR Stock Analysis - Frequently Asked Questions How have ZSQR shares performed this year? Coeptis Therapeutics' stock was trading at $14.25 at the start of the year. Since then, ZSQR shares have decreased by 68.1% and is now trading at $4.54. How were Coeptis Therapeutics' earnings last quarter? Coeptis Therapeutics Holdings, Inc. (NASDAQ:ZSQR) posted its quarterly earnings results on Thursday, August, 13th. The company reported ($0.28) earnings per share (EPS) for the quarter. The company earned $1.58 million during the quarter. Coeptis Therapeutics had a negative trailing twelve-month return on equity of 49.45% and a negative net margin of 773.72%. When did Coeptis Therapeutics' stock split? Coeptis Therapeutics shares reverse split before market open on Tuesday, December 31st 2024.The 1-20 reverse split was announced on Friday, December 27th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, December 30th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Coeptis Therapeutics? Shares of ZSQR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Coeptis Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Coeptis Therapeutics investors own include Avino Silver & Gold Mines (ASM), PayPal (PYPL), Tesla (TSLA), Meta Platforms (META), 3M (MMM), P3 Health Partners (PIII). Company Calendar Last Earnings8/13/2026Today9/28/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 ZSQR's financial health is in the Red zone, according to TradeSmith. ZSQR has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorTechnology Industry Software Sub-IndustryApplication Software Current SymbolNASDAQ:ZSQR Previous SymbolNASDAQ:COEP CIK1759186 Webir.zsquaredinc.com Phone(954) 400-9994FaxN/AEmployees6Year FoundedN/AProfitability EPS (Trailing Twelve Months)($1.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$11.92 million Net Margins-773.72% Pretax Margin-953.59% Return on Equity-49.45% Return on Assets-46.88% Debt Debt-to-Equity RatioN/A Current Ratio7.66 Quick Ratio7.66 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.63 per share Price / Book1.73Miscellaneous Outstanding Shares53,000,000Free Float40,148,000Market Cap$240.62 million OptionableNot Optionable Beta-0.25 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:ZSQR) was last updated on 9/28/2026 by MarketBeat.com Staff. From Our PartnersElon Musk’s Hushed FCC Filing. Dec 8th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This pa...Digest Publishing | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | Sponsored"How Much Can I Actually Spend Each Year With $2.5M Saved?"Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coeptis Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coeptis Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
